A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Phase 1

Completed

• Conditions: Type 2 Diabetes
• Interventions: Drug: ARRY-403, glucokinase activator; oral; Drug: Placebo; oral

• Registration Number: NCT00859755
• Lead Sponsor: Array BioPharma

Brief Summary

This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36 patients from the US will be enrolled in this study.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-03-06
• Study First Submitted QC: 2009-03-09
• Study First Posted: 2009-03-11
• Primary Completion: 2009-07
• Status Verified: 2012-08
• Last Update Submitted: 2012-08-29
• Last Update Posted: 2012-08-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

• Male or female with willingness and ability to use protocol-specified methods of contraception, except females of nonchildbearing potential.
• Diagnosis of Type 2 diabetes less than 5 years prior to study start.
• HbA1c ≥ 6.5% and ≤ 10%.
• BMI ≥ 25 and ≤ 40.0 kg/m2.
• Additional criteria exist.

Key

Exclusion Criteria

• Recent history (i.e., less than 6 months) or concomitant/ongoing clinically significant hematologic, renal, pulmonary, gastrointestinal, hepatic, psychiatric, neurologic, dermatologic, or allergic disease (including drug allergies that are clinically significant and not remote, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Significant cardiac disease, myocardial infarction within 6 months of study start, unstable angina, congestive heart failure, known arrhythmias of ventricular etiology, unexplained syncope or syncope/seizures related to arrhythmia.
• History of gastric surgery, vagotomy, bowel resection, or any surgical procedure that might interfere with gastrointestinal motility, pH, or absorption.
• Active infectious diseases including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). Past history and inactive hepatitis B and C, as confirmed by serological testing, are allowed.
• A positive test for drugs or alcohol.
• Women who are pregnant or breastfeeding.
• Donation or loss of ≥ 550 mL of blood (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to first dose of study drug.
• Additional criteria exist.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ARRY-403	ARRY-403, glucokinase activator; oral	-
Placebo	Placebo; oral	-

Primary Outcome Measures

Name	Time	Method
Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.	Duration of study
Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.	Day 1, Day 2

Secondary Outcome Measures

Name	Time	Method
Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.	Day 1, Day 2
Assess the ability of the study drug to improve glucose tolerance as determined by blood glucose monitoring during a standardized meal challenge.	Day 1, Day 2
Assess the excretion of the study drug and metabolites in urine following dosing.	Day 1, Day 2

Trial Locations

Locations (1)

Profil Institute for Clinical Research, Inc.; 🇺🇸 Chula Vista, California, United States